BAGSVAED, Denmark I May 22, 2015 I Today, Novo Nordisk announced the headline results from the SCALE(TM) Obesity and Prediabetes three-year extension trial in adults with obesity or who were overweight with comorbidities, and had prediabetes at baseline. The trial met its primary endpoint, demonstrating that ongoing treatment with Saxenda® (liraglutide 3 mg) in combination with a reduced-calorie diet and increased physical activity delayed the onset of type 2 diabetes, compared with placebo (diet and exercise alone).
Over the course of this 160-week, randomised, blinded phase 3a trial, the time to onset of type 2 diabetes was 2.6 times longer with Saxenda® compared with placebo treatment. In addition, the risk of developing type 2 diabetes was reduced by approximately 80% and statistically significant (p<0.0001) for those being treated with Saxenda®.
“People with obesity are at an increased risk of developing type 2 diabetes, which is a serious disease,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer. “We are encouraged by these three-year data demonstrating that Saxenda® can help to delay the onset of type 2 diabetes, in addition to providing sustained long-term weight loss.”
Read the full release
SOURCE: Novo Nordisk
Post Views: 26
BAGSVAED, Denmark I May 22, 2015 I Today, Novo Nordisk announced the headline results from the SCALE(TM) Obesity and Prediabetes three-year extension trial in adults with obesity or who were overweight with comorbidities, and had prediabetes at baseline. The trial met its primary endpoint, demonstrating that ongoing treatment with Saxenda® (liraglutide 3 mg) in combination with a reduced-calorie diet and increased physical activity delayed the onset of type 2 diabetes, compared with placebo (diet and exercise alone).
Over the course of this 160-week, randomised, blinded phase 3a trial, the time to onset of type 2 diabetes was 2.6 times longer with Saxenda® compared with placebo treatment. In addition, the risk of developing type 2 diabetes was reduced by approximately 80% and statistically significant (p<0.0001) for those being treated with Saxenda®.
“People with obesity are at an increased risk of developing type 2 diabetes, which is a serious disease,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer. “We are encouraged by these three-year data demonstrating that Saxenda® can help to delay the onset of type 2 diabetes, in addition to providing sustained long-term weight loss.”
Read the full release
SOURCE: Novo Nordisk
Post Views: 26
